Chemnitz

• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• Pembro-FLASH Recruiting
  2022-501458-13-01 4 2026-04-29 Advanced Stage of Classic Hodgkin Lymphoma
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou … Recruiting
  2025-520771-59-00 4 2026-02-03 Atopic Dermatitis
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans … Recruiting
  2023-507879-21-00 4 2026-01-19 AML and MDS undergoing allogeneic Transplantation
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious … Recruiting
  2025-522347-18-00 4 2025-11-26 Major Depressive Disorder (MDD), with or without Anxious Distress
• Silexan® in mild to moderate major depressive disorder Recruiting
  2025-521744-37-00 5 2025-11-17 Mild to moderate major depressive disorder
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles … Recruiting
  2024-518156-24-00 5 2025-11-10 Atopic Dermatitis
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520747-32-00 5 2025-10-29 Mild to moderate Alzheimer’s Disease
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici … Recruiting
  2024-519929-38-00 4 2025-10-27 Metastatic Colorectal Cancer without liver metastases
• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 5 2025-10-17 Neovascular Age-Related Macular Degeneration (nAMD)
• Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD- … Recruiting
  2024-520264-33-00 5 2025-10-07 Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 High-grade B-cell lymphoma (HGBL)
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants … Recruiting
  2024-519152-82-00 5 2025-09-03 Relapsed/Refractory Follicular Lymphoma
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease

Showing 25–48 of 200 trials